SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that ...

SGR-1505 was designed using Schrödinger's computational platform at scale and was discovered approximately 10 months after the company started its MALT1 program. A Phase 1 study in patients with ...

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025; Marks the ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current ...

Most gene therapies being studied for eye diseases are in earlier phases of development, and a third of the gene therapies ...

Both small animal models and microphysiological systems gain in sophistication and value as they expedite in vivo preclinical testing.

The four phases help to ensure the trial's safety and effectiveness. ... If the preclinical research suggests the treatment may be safe and effective for humans, Phase 1 can begin.

Understanding the preclinical phase Though Neurodegenerative disorders are often diagnosed late, neurological research suggests that the pathology of these conditions begins long before the ...

The phase out of animal testing will start with biologic drugs, such as monoclonal antibodies, the FDA said Thursday.In place of this preclinical research, the agency encourages drug companies to ...

Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in people with Parkinson’s disease; biomarker analysis to be conducted in Q2 2025 ...